血液系统恶性肿瘤高危中性粒细胞减少患者早期停用抗生素后的安全性与发热复发风险:一项多中心观察性研究
这项回顾性多中心观察性研究比较了高危中性粒细胞减少伴发热待查患者按ECIL-4推荐早期停用抗生素与历史队列的安全性差异。结果显示两组发热复发率、ICU入住率、感染性休克及30天死亡率均无显著差异,但ECIL-4队列菌血症比例更高、抗生素使用天数更低。
要点
- 高危中性粒细胞减少伴发热待查患者按ECIL-4推荐早期停用抗生素,发热复发率与未停药历史队列无显著差异。
- ECIL-4队列发热复发时菌血症比例更高(27.1% vs 11.8%,P<0.01),抗生素使用天数更低(15.5 vs 19.9天,P<0.001)。
- 早期停药后,小肠结肠炎与发热复发相关(HR=2.31),III-IV级口腔黏膜炎与菌血症相关(HR=2.26)。
核心结论
- 高危中性粒细胞减少患者发生发热待查后,遵循ECIL-4推荐早期停用抗生素似乎是安全的,且黏膜损伤与发热复发和菌血症相关。
- 作者认为需要前瞻性干预性研究来评估这一策略在高危中性粒细胞减少患者中的应用。
研究设计与样本
- 回顾性多中心观察性研究,为期2年,比较按ECIL-4推荐早期停用抗生素的队列与历史队列。
- ECIL-4队列纳入147例患者,共170次化疗后中性粒细胞减少发作;历史队列为178次未停用抗生素的中性粒细胞减少发作。
- 采用以中性粒细胞恢复为删失点的Cox比例风险模型分析发热复发相关因素。
主要发现
- ECIL-4队列患者主要诊断为急性白血病(104例,71%)。
- 发热复发率ECIL-4队列71.2%(121/170) vs 历史队列71.3%(127/178),P=0.97。
- ICU入住率ECIL-4队列6.5%(11/170) vs 历史队列11.2%(20/178),P=0.17。
- 感染性休克发生率ECIL-4队列0.6%(1/170) vs 历史队列3.9%(7/178),P=0.07;30天死亡率ECIL-4队列1.4%(2/147) vs 历史队列2.7%(4/150),P=0.084。
- ECIL-4队列发热复发时菌血症比例更高[27.1%(46/170) vs 11.8%(21/178),P<0.01],抗生素使用天数显著更低(15.5 vs 19.9天,P<0.001)。
关键数值与推荐
- 早期停用抗生素后,小肠结肠炎与发热复发相关[HR=2.31(95%CI=1.4-3.8),P<0.001]。
- III-IV级口腔黏膜炎与菌血症相关[HR=2.26(95%CI=1.22-4.2),P=0.01]。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early antibiotic discontinuation according to the Fourth European Conference on Infections in Leukaemia (ECIL-4) recommendations is not systematically applied in high-risk neutropenic patients with haematological malignancies. METHODS: A retrospective multicentre observational study was conducted over 2 years to evaluate the safety of early antibiotic discontinuation for fever of unknown origin (FUO) during neutropenia after induction chemotherapy or HSCT, in comparison with a historical cohort. We used Cox proportional hazards models, censored on neutropenia resolution, to analyse factors associated with febrile recurrence. RESULTS: Among 147 included patients in the ECIL-4 cohort, mainly diagnosed with acute leukaemia (n = 104, 71%), antibiotics were discontinued during 170 post-chemotherapy neutropenic episodes. In comparison with the historical cohort of 178 episodes of neutropenia without antibiotic discontinuation, no significant differences were observed regarding febrile recurrences [71.2% (121/170) versus 71.3% (127/178), P = 0.97], admission in ICUs [6.5% (11/170) versus 11.2% (20/178), P = 0.17], septic shock [0.6% (1/170) versus 3.9% (7/178), P = 0.07] and 30 day mortality [1.4% (2/147) versus 2.7% (4/150), P = 0.084]. In the ECIL-4 cohort, the rate of bacteraemia in case of febrile recurrence was higher [27.1% (46/170) versus 11.8% (21/178), P < 0.01] and antibiotic consumption was significantly lower (15.5 versus 19.9 days, P < 0.001). After early antibiotic discontinuation according to ECIL-4 recommendations, enterocolitis was associated with febrile recurrence [HR = 2.31 (95% CI = 1.4-3.8), P < 0.001] and stage III-IV oral mucositis with bacteraemia [HR = 2.26 (95% CI = 1.22-4.2), P = 0.01]. CONCLUSIONS: After an FUO episode in high-risk neutropenia, compliance with ECIL-4 recommendations for early antibiotic discontinuation appears to be safe and mucosal damage was associated with febrile recurrence and bacteraemia. Prospective interventional studies are warranted to assess this strategy in high-risk neutropenic patients.
引用
- Paret R, Le Bourgeois A, Guillerm G, et al. Safety and risk of febrile recurrence after early antibiotic discontinuation in high-risk neutropenic patients with haematological malignancies: a multicentre observational study. J Antimicrob Chemother. 2022. PMID: 35748614. doi:10.1093/jac/dkac190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。